Envveno Medical Corp Up 0.3% To $4.93 After Earnings Miss

Envveno Medical Corp (NVNO) said after close Monday that it lost $0.58 per share in quarter two 2023. The company reported $0.00 in revenue

In the same quarter a year ago, the company lost $0.63 per share on revenue of $0.00.

The stock is up 0.3% to $4.93 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Envveno Medical Corp has performed a little below average during the past few months. Before the report, Envveno Medical Corp received a Long-Term Technical Rank by InvestorsObserver of 43, putting it in the bottom half of stocks. The firm was recently trading at a 52-week low of $2.51 on June 7, 2023 and set a 52-week high on September 15, 2022 at $7.93.

enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).